CN108434464A - A kind of RGD- perfluorocarbons breast magnetic resonance imaging developer and its preparation method and application - Google Patents
A kind of RGD- perfluorocarbons breast magnetic resonance imaging developer and its preparation method and application Download PDFInfo
- Publication number
- CN108434464A CN108434464A CN201810351309.3A CN201810351309A CN108434464A CN 108434464 A CN108434464 A CN 108434464A CN 201810351309 A CN201810351309 A CN 201810351309A CN 108434464 A CN108434464 A CN 108434464A
- Authority
- CN
- China
- Prior art keywords
- rgd
- preparation
- nano
- emulsions
- breast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 57
- 210000000481 breast Anatomy 0.000 title claims abstract description 28
- 238000002595 magnetic resonance imaging Methods 0.000 title description 26
- 239000007908 nanoemulsion Substances 0.000 claims abstract description 60
- 239000008363 phosphate buffer Substances 0.000 claims abstract description 23
- 239000006210 lotion Substances 0.000 claims abstract description 14
- -1 perfluoro bromide octane Chemical compound 0.000 claims abstract description 9
- 239000007853 buffer solution Substances 0.000 claims abstract description 7
- 239000008367 deionised water Substances 0.000 claims abstract description 7
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 7
- 239000007850 fluorescent dye Substances 0.000 claims abstract description 7
- 239000003550 marker Substances 0.000 claims abstract description 7
- 238000012360 testing method Methods 0.000 claims abstract description 7
- 238000002604 ultrasonography Methods 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 4
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 6
- 239000012498 ultrapure water Substances 0.000 claims description 6
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 2
- 229940083466 soybean lecithin Drugs 0.000 claims description 2
- TUKRPLMDZOHSQQ-UHFFFAOYSA-N C(CCCCCCC)Br.[F] Chemical compound C(CCCCCCC)Br.[F] TUKRPLMDZOHSQQ-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 8
- 238000003384 imaging method Methods 0.000 abstract description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 7
- 201000005202 lung cancer Diseases 0.000 abstract description 6
- 208000020816 lung neoplasm Diseases 0.000 abstract description 6
- 229920001983 poloxamer Polymers 0.000 abstract description 5
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 230000010355 oscillation Effects 0.000 abstract description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 abstract 1
- 238000013399 early diagnosis Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000002296 dynamic light scattering Methods 0.000 description 12
- 238000001514 detection method Methods 0.000 description 9
- 238000010586 diagram Methods 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 6
- 235000020195 rice milk Nutrition 0.000 description 5
- 235000013339 cereals Nutrition 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- 229920006926 PFC Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 230000002102 hyperpolarization Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000004480 129Xe NMR spectroscopy Methods 0.000 description 1
- CVOFKRWYWCSDMA-UHFFFAOYSA-N 2-chloro-n-(2,6-diethylphenyl)-n-(methoxymethyl)acetamide;2,6-dinitro-n,n-dipropyl-4-(trifluoromethyl)aniline Chemical compound CCC1=CC=CC(CC)=C1N(COC)C(=O)CCl.CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O CVOFKRWYWCSDMA-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 239000002616 MRI contrast agent Substances 0.000 description 1
- 238000012307 MRI technique Methods 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 230000005311 nuclear magnetism Effects 0.000 description 1
- BDDIUTHMWNWMRJ-UHFFFAOYSA-N octane;hydrobromide Chemical compound Br.CCCCCCCC BDDIUTHMWNWMRJ-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000032895 transmembrane transport Effects 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
- A61K49/0078—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion microemulsion, nanoemulsion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nanotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of preparation methods of RGD perfluorocarbons breast MRI developers, include the following steps：(1) preparation of nano-emulsion：First phosphatide and pluronic are dissolved in phosphate buffer, then perfluoro bromide octane is added in buffer solution, and is handled 5 10 minutes in Ultrasound Instrument, then is vibrated 10 15 minutes with test tube oscillator, thick lotion is obtained；Thick lotion deionized water is diluted 20 times later, then is extruded 2 times by miillpore filter, nano-emulsion is obtained；(2) preparation of RGD nano-emulsions：Cholesterol PEG2000 RGD are added in nanoemulsions, oscillation on shaking table is subsequently placed in and obtains targeted nano breast；(3) preparation of the RGD nano-emulsions of fluorescent marker：The fluorescent dye DiI of a concentration of 5mg/mL is added into targeted nano breast, is subsequently placed on shaking table and vibrates, obtains the RGD nano-emulsions of DiI labels.The method of the present invention is simple and efficient, and developer high sensitivity, good biocompatibility, the lung cancer-targeted tumour of energy of preparation carry out MR imagings, can be applied to the early diagnosis and therapy of lung cancer.
Description
Technical field
The invention belongs to nmr imaging technique fields, and in particular to a kind of RGD- perfluorocarbons breast MRI developments
Agent and its preparation method and application.
Background technology
It is occupied an important position at present using nmr imaging technique research human lesion diagnosis in medical domain, nuclear-magnetism is total
Shake (NMR) be a kind of technology that can non-invasively detect opaque sample and avoid ionising radiation.NMR is usually using proton
Signal is generated, but its application is limited by its poor sensitivity, and there is very strong background signal to interfere in vivo.Institute
With heteronuclear MRI is (such as13C,31P,19F,129Xe) technology is increasingly valued by people.
Nano-emulsion has good biocompatibility, cell transmembrane transport capacity as a kind of novel nano material, can
Applied to the diagnosis of tumour and as pharmaceutical carrier.Perfluocarbon (PFCs) nano-emulsion conduct19F MRI tracers are wide
General application.Perfluoro bromide octane (PFOB) is a kind of avirulent PFCs, it is possible to provide stronger F signals are even more widely used in
Detect tumour cell, tissue and the 19F MRI imagings to vivo tumor.In addition, PFOB has preferable dissolubility, xenon to Xe
Gas is a kind of ideal medium, because it is a kind of inertia, nontoxic gas, without background signal in human body.129The day of Xe
Right abundance is 26.4%, can generate hyperpolarization by homemade polarization device129Xe gases.By hyperpolarization129Xe and CEST skills
Art is combined the sensitivity that can reach superelevation, minimum to be detected under picomolar concentrations129Xe contrast agent.Has document report
PFOB can be applied to129Xe MRI contrast agents.
Using perfluoro bromide octane (PFOB) as129The carrier of Xe, it has good biocompatibility, nontoxic, internal metabolism fast
The advantages that, as 129Xe/19F double-channel multifunctional developers, the sensitivity with superelevation is used for PFOB nano-emulsions129Xe MRI
And19F MRI imagings.Preparation method is simple, material is easy to get preferable biocompatibility, can be applied to the core in organism
Magnetic resonance imaging.
Invention content
The invention reside in overcome the deficiencies in the prior art, it is therefore an objective to be to provide a kind of RGD- perfluorocarbons breast MRI
Developer and its preparation method and application；PFOB nano-emulsions provided by the invention combine129Xe MRI and19Two kinds of magnetic of F MRI are total
Shake imaging method, and quotes the strategy for the targeting diagnosis that RGD ligands are combined with the receptor-specific on cancer cell, makes nano-emulsion
The tumor cell of selectivity.Pass through129Xe MRI and19F MRI techniques realize the targeting diagnosis to lung cancer tumor.The development
Agent has hypersensitivity and preferable biocompatibility.The nano-emulsion preparation method is simple, and raw material is cheap and easily-available, is suitable for
Internal magnetic resonance imaging.
To solve the above-mentioned problems, the technical solution that the present invention takes is：
A kind of preparation method of RGD- perfluorocarbons breast MRI developers, includes the following steps：
(1) preparation of nano-emulsion：To first the phosphatide that phosphate buffer 4wt% accounted for and it account for phosphate buffer 0.5wt%
Pluronic F-68 be dissolved in 1ml phosphate buffers (PBS), then will account for phosphate buffer 1 0wt%-20wt%
Perfluoro bromide octane (PFOB) be added in above-mentioned buffer solution, and handled 5-10 minutes in Ultrasound Instrument, then use test tube oscillator
Oscillation 10-15 minutes, obtains thick lotion；The thick lotion of preparation deionized water is diluted 20 times later, then is squeezed by miillpore filter
System 2 times, obtains nano-emulsion and is denoted as NPs；
(2) preparation of RGD- nano-emulsions：Cholesterol-PEG2000-RGD is added to the nanoemulsions of step (1) preparation
In, it is subsequently placed on shaking table the velocity fluctuation with 300rpm and obtains within 1 hour targeted nano breast NPs-RGD；
(3) preparation of the RGD nano-emulsions of fluorescent marker：It is added in the targeted nano breast prepared to step (2) a concentration of
The fluorescent dye DiI of 5mg/mL is subsequently placed on shaking table the velocity fluctuation 1 hour with 300rpm, and the RGD- for obtaining DiI labels receives
Rice milk.
Preferably, the preparation method of the cholesterol-PEG2000-RGD is：By cholesterol-PEG2000-Mal and RGDyc
In molar ratio 10:1-1:1 is added in 1ml PBS, is placed in velocity fluctuation 20-24 hours on shaking table with 300rpm at room temperature, so
It is dialysed in ultra-pure water with bag filter afterwards and removes unreacted RGDyc molecules, freeze-dried machine is lyophilized to obtain targeted molecular courage
Sterol-PEG2000-RGD.
Preferably, the phosphatide is soybean lecithin (Lipoid S75).
Preferably, a concentration of 5mM of the phosphate buffer, pH 7.4.
Preferably, the aperture of the miillpore filter is 0.22 μm.
Preferably, the addition of the cholesterol-PEG2000-RGD and the molar ratio of phosphatide are 1：20.
Preferably, the mass ratio of phosphatide and F-68 are 8 in step (1)：1.
Preferably, the mass ratio of the phosphatide and perfluoro bromide octane (PFOB) is 1:2.5-1:5.
In addition, the RGD- perfluorocarbon breast MRI developers being prepared by the method are also claimed in the present invention
And the developer is applied to the early mri diagnosis of lung cancer tumor.
Compared with prior art, the present invention has apparent advantageous effect below：
(1) present invention does membrane material using S75 phosphatide, is modified with cholesterol-PEG2000-RGD molecules, using super
Sound and the method for oscillation prepare nano-emulsion, and the wherein addition of F-68 can be such that microemulsion structure more stablizes, and material is cheap and easily-available, system
Preparation Method is simple and has good biocompatibility；
(2) nano-emulsion for preparing of the present invention is simultaneously as 129Xe MRI and 19F MRI developers and optical imagery development
Agent is a kind of 129Xe/19F binary channels, bimodal MRI developers；
(3) it is used as 129Xe Hyper CEST developers, nano-emulsion of the present invention that there is the high sensitivity of superelevation, can rub in skin
MRI imagings are carried out to lung carcinoma cell under your concentration.The nanometer is demonstrated by 129Xe MRI and 19F MRI and optical imagery
Breast there is preferable targeting, the developer can be applied to the early mri diagnosis of lung cancer tumor lung cancer tumor.
Description of the drawings
Fig. 1 is the dynamic light scattering diagram of NPs-RGD nano-emulsions prepared by the embodiment of the present invention 1；
Fig. 2 is the transmission electron microscope picture of NPs-RGD nano-emulsions prepared by the embodiment of the present invention 1；
Fig. 3 is the UV absorption pop figure of NPs-RGD nano-emulsions prepared by the embodiment of the present invention 1；
Fig. 4 is the fluorescence emission spectrogram of compound of NPs-RGD nano-emulsions prepared by the embodiment of the present invention 1；
Fig. 5 is NPs-RGD nano-emulsions prepared by the embodiment of the present invention 119F spectrograms；
Fig. 6 is NPs-RGD nano-emulsions prepared by the embodiment of the present invention 1129Xe NMR spectras；
Fig. 7 is NPs-RGD nano-emulsions prepared by the embodiment of the present invention 1129Xe Hyper CEST spectrograms；
Fig. 8 is after NPs-RGD prepared by the embodiment of the present invention 1 is incubated with normal cell and tumour cell respectively129Xe MRI and19F MRI spectrograms；
Fig. 9 is the dynamic light scattering diagram of NPs-RGD nano-emulsions prepared by the embodiment of the present invention 2；
Figure 10 is the dynamic light scattering diagram of NPs-RGD nano-emulsions prepared by the embodiment of the present invention 3；
Figure 11 is the dynamic light scattering diagram of NPs-RGD nano-emulsions prepared by the embodiment of the present invention 4.
Specific implementation mode
Below with specific embodiment, the present invention is further explained.Following embodiments are merely to illustrate the present invention and do not have to
In limiting the scope of the invention.
Embodiment 1
A kind of preparation method of RGD- perfluorocarbons breast MRI developers, includes the following steps：
(1) preparation of nano-emulsion：It is dense that the phosphatide Lipoid S75 and 5mg pluronics F-68 of 40mg is first dissolved in 1mL
Degree is that the perfluoro bromide octane of 0.2g (PFOB) is then added to above-mentioned buffer solution in the phosphate buffer of 5mM, pH=7.4
In, and handled 8 minutes in power is 170W Ultrasound Instruments, then vibrated 12 minutes with test tube oscillator, obtain thick lotion；It later will system
Standby thick lotion deionized water dilutes 20 times, then is extruded 2 times by the miillpore filter that aperture is 0.22 μm, obtains nano-emulsion note
For NPs；
(2) preparation of RGD- nano-emulsions：Cholesterol-the PEG2000-RGD of 1.2mg is added to 3mL steps (1) preparation
In nanoemulsions, it is subsequently placed on shaking table the velocity fluctuation with 300rpm and obtains within 1 hour targeted nano breast NPs-RGD；
(3) preparation of the RGD nano-emulsions of fluorescent marker：It is added in the targeted nano breast prepared to 3ml steps (3) a concentration of
The fluorescent dye DiI of 5mg/mL is subsequently placed on shaking table the velocity fluctuation 1 hour with 300rpm, and the RGD- for obtaining DiI labels receives
Rice milk.
Wherein, the preparation method of the cholesterol-PEG2000-RGD is：By 21.4mg cholesterol-PEG2000-Mal and
5mg RGDyc are added in 1ml PBS, are placed on shaking table the velocity fluctuation 20 hours with 300rpm at room temperature.Then with retention point
Son amount, which is dialysed for 1000Da bag filters in ultra-pure water, removes unreacted RGDyc molecules, and freeze-dried machine is lyophilized to obtain target
To molecule cholesterol-PEG2000-RGD.
NPs-RGD prepared by the present embodiment 1 carries out dynamic light scattering detection, dynamic light scattering diagram such as Fig. 1 institutes of gained
Show, it is 195nm to be averagely hydrated grain size.
NPs-RGD prepared by the present embodiment 1 is scanned with transmission electron microscope, the transmission electron microscope picture of gained as shown in Fig. 2,
It can be seen from the figure that, NPs good dispersions manufactured in the present embodiment, uniform particle diameter.There are the structure of one layer of similar film, explanation in surface
PFG-RGD molecular modifications are to the surface of nano-emulsion.
NPs-RGD prepared by the present embodiment 1 carries out UV absorbance detection, uv absorption spectra such as Fig. 3 institutes of gained
Show, RGD characterization of molecules absorption peaks are detected at 275nm, illustrates that RGD molecules successfully modify nano-emulsion surface.
NPs-RGD prepared by the present embodiment 1 carries out fluorescence emission spectrum detection, as can be seen from Figure 4 emission maximum
Wavelength is 570nm.
NPs-RGD prepared by the present embodiment 1 carries out fluorine spectrum detection, and the fluorine of gained composes 17 F as shown in figure 5, PFOB
Show 8 groups of peaks.
NPs-RGD prepared by the present embodiment 1 carries out 129Xe H NMR spectroscopy detections, as shown in fig. 6, Xe is in PFOB nano-emulsions
In signal at 106ppm, the Xe signals in aqueous solution are in 195ppm.
NPs-RGD prepared by the present embodiment 1 is carried out129Xe Hyper CEST spectrum detections, as shown in fig. 7,106ppm has
One stronger CEST signal, comes from signals of the Xe in PFOB nano-emulsions.
NPs-RGD prepared by the present embodiment 1 is surveyed after being incubated respectively with normal cell and tumour cell129Xe MRI
Spectrogram, as shown in Figure 8 A, tumour cell have stronger CEST signals, show very bright signal.And normal cell does not have substantially
Signal illustrates that NPs-RGD has selectively targeted effect to tumour cell.It does19F MRI imaging results are as shown in Figure 8 B, tumour
Cell has stronger19F signals, normal cell do not have signal, again demonstrate targeting and MRI of the NPs-RGD to tumour cell
It is imaged property.
Embodiment 2
A kind of preparation method of RGD- perfluorocarbons breast MRI developers, includes the following steps：
(1) preparation of nano-emulsion：It is dense that the phosphatide Lipoid S75 and 5mg pluronics F-68 of 40mg is first dissolved in 1mL
Degree is that the perfluoro bromide octane of 0.1g (PFOB) is then added to above-mentioned buffer solution in the phosphate buffer of 5mM, pH=7.4
In, and handled 5 minutes in power is 170W Ultrasound Instruments, then vibrated 10 minutes with test tube oscillator, obtain thick lotion；It later will system
Standby thick lotion deionized water dilutes 20 times, then is extruded 2 times by the miillpore filter that aperture is 0.22 μm, obtains nano-emulsion note
For NPs；
(2) preparation of RGD- nano-emulsions：Cholesterol-the PEG2000-RGD of 1.2mg is added to 3mL steps (1) preparation
In nanoemulsions, it is subsequently placed on shaking table the velocity fluctuation with 300rpm and obtains within 1 hour targeted nano breast NPs-RGD；
(3) preparation of the RGD nano-emulsions of fluorescent marker：It is added in the targeted nano breast prepared to 3ml steps (3) a concentration of
The fluorescent dye DiI of 5mg/mL is subsequently placed on shaking table the velocity fluctuation 1 hour with 300rpm, and the RGD- for obtaining DiI labels receives
Rice milk.
Wherein, the preparation method of the cholesterol-PEG2000-RGD is：By 8.5mg cholesterol-PEG2000-Mal and
2mg RGDyc are added in 1ml PBS, are placed on shaking table the velocity fluctuation 20 hours with 300rpm at room temperature.Then with retention point
Son amount, which is dialysed for 1000Da bag filters in ultra-pure water, removes unreacted RGDyc molecules, and freeze-dried machine is lyophilized to obtain target
To molecule cholesterol-PEG2000-RGD.
NPs-RGD prepared by the present embodiment 2 carries out dynamic light scattering detection, dynamic light scattering diagram such as Fig. 9 institutes of gained
Show, it is 205nm to be averagely hydrated grain size.
Embodiment 3
A kind of preparation method of RGD- perfluorocarbons breast MRI developers, includes the following steps：
(1) preparation of nano-emulsion：It is dense that the phosphatide Lipoid S75 and 5mg pluronics F-68 of 40mg is first dissolved in 1mL
Degree is that the perfluoro bromide octane of 0.2g (PFOB) is then added to above-mentioned buffer solution in the phosphate buffer of 5mM, pH=7.4
In, and handled 10 minutes in power is 170W Ultrasound Instruments, then vibrated 15 minutes with test tube oscillator, obtain thick lotion；Later will
The thick lotion prepared deionized water dilutes 20 times, then is extruded 2 times by the miillpore filter that aperture is 0.22 μm, obtains nano-emulsion
It is denoted as NPs；
(2) preparation of RGD- nano-emulsions：Cholesterol-the PEG2000-RGD of 0.8mg is added to 2mL steps (1) preparation
In nanoemulsions, it is subsequently placed on shaking table the velocity fluctuation with 300rpm and obtains within 1 hour targeted nano breast NPs-RGD；
(3) preparation of the RGD nano-emulsions of fluorescent marker：It is added in the targeted nano breast prepared to 3ml steps (3) a concentration of
The fluorescent dye DiI of 5mg/mL is subsequently placed on shaking table the velocity fluctuation 1 hour with 300rpm, and the RGD- for obtaining DiI labels receives
Rice milk.
Wherein, the preparation method of the cholesterol-PEG2000-RGD is：By 33mg cholesterol-PEG2000-Mal and
1.4mg RGDyc are added in 1ml PBS, are placed on shaking table the velocity fluctuation 20 hours with 300rpm at room temperature.Then with retention
Molecular weight dialyses in ultra-pure water for 1000Da bag filters and removes unreacted RGDyc molecules, and freeze-dried machine is lyophilized to obtain
Targeted molecular cholesterol-PEG2000-RGD.
NPs-RGD prepared by the present embodiment 3 carries out dynamic light scattering detection, dynamic light scattering diagram such as Figure 10 institutes of gained
Show, it is 210nm to be averagely hydrated grain size.
Embodiment 4
A kind of preparation method of RGD- perfluorocarbons breast MRI developers, includes the following steps：
(1) preparation of nano-emulsion：It is dense that the phosphatide Lipoid S75 and 10mg pluronics F-68 of 80mg is first dissolved in 1mL
Degree is that the perfluoro bromide octane of 0.4g (PFOB) is then added to above-mentioned buffer solution in the phosphate buffer of 5mM, pH=7.4
In, and handled 10 minutes in power is 170W Ultrasound Instruments, then vibrated 15 minutes with test tube oscillator, obtain thick lotion；Later will
The thick lotion prepared deionized water dilutes 20 times, then is extruded 2 times by the miillpore filter that aperture is 0.22 μm, obtains nano-emulsion
It is denoted as NPs；
(2) preparation of RGD- nano-emulsions：Cholesterol-the PEG2000-RGD of 1.2mg is added to 3mL steps (1) preparation
In nanoemulsions, it is subsequently placed on shaking table the velocity fluctuation with 300rpm and obtains within 1 hour targeted nano breast NPs-RGD；
(3) preparation of the RGD nano-emulsions of fluorescent marker：It is added in the targeted nano breast prepared to 3ml steps (3) a concentration of
The fluorescent dye DiI of 5mg/mL is subsequently placed on shaking table the velocity fluctuation 1 hour with 300rpm, and the RGD- for obtaining DiI labels receives
Rice milk.
Wherein, the preparation method of the cholesterol-PEG2000-RGD is：By 33mg cholesterol-PEG2000-Mal and
1.4mg RGDyc are added in 1ml PBS, are placed on shaking table the velocity fluctuation 20 hours with 300rpm at room temperature.Then with retention
Molecular weight dialyses in ultra-pure water for 1000Da bag filters and removes unreacted RGDyc molecules, and freeze-dried machine is lyophilized to obtain
Targeted molecular cholesterol-PEG2000-RGD.
NPs-RGD prepared by the present embodiment 4 carries out dynamic light scattering detection, dynamic light scattering diagram such as Figure 11 institutes of gained
Show, it is 215nm to be averagely hydrated grain size.
Above-described embodiment simply to illustrate that the present invention technical concepts and features, it is in the art the purpose is to be to allow
Those of ordinary skill cans understand the content of the present invention and implement it accordingly, and it is not intended to limit the scope of the present invention.It is all
It is the equivalent changes or modifications made by the essence according to the content of present invention, should all covers within the scope of the present invention.
Claims (9)
1. a kind of preparation method of RGD- perfluorocarbons breast MRI developers, which is characterized in that include the following steps：
(1) preparation of nano-emulsion：To first the phosphatide that phosphate buffer 4wt% accounted for and it account for the general of phosphate buffer 0.5wt%
Lang Nike F-68 are dissolved in 1ml phosphate buffers (PBS), then will account for the complete of phosphate buffer 1 0wt%-20wt%
Fluorine bromooctane (PFOB) is added in above-mentioned buffer solution, and is handled 5-10 minutes in Ultrasound Instrument, then is vibrated with test tube oscillator
10-15 minutes, obtain thick lotion；The thick lotion of preparation deionized water is diluted 20 times later, then 2 are extruded by miillpore filter
It is secondary, it obtains nano-emulsion and is denoted as NPs；
(2) preparation of RGD- nano-emulsions：Cholesterol-PEG2000-RGD is added in the nanoemulsions of step (1) preparation, so
It is placed on shaking table the velocity fluctuation with 300rpm and obtains within 1 hour targeted nano breast NPs-RGD；
(3) preparation of the RGD nano-emulsions of fluorescent marker：A concentration of 5mg/mL is added in the targeted nano breast prepared to step (2)
Fluorescent dye DiI, be subsequently placed on shaking table the velocity fluctuation 1 hour with 300rpm, obtain the RGD- nano-emulsions of DiI labels.
2. preparation method according to claim 1, which is characterized in that the preparation method of the cholesterol-PEG2000-RGD
For：By cholesterol-PEG2000-Mal and RGDyc in molar ratio 10:1-1:1 is added in 1ml PBS, is placed in shaking table at room temperature
On with velocity fluctuation 20-24 hours of 300rpm, it is then RGDyc points unreacted with bag filter removal of dialysing in ultra-pure water
Son, freeze-dried machine are lyophilized to obtain targeted molecular cholesterol-PEG2000-RGD.
3. preparation method according to claim 1, which is characterized in that the phosphatide is soybean lecithin (Lipoid
S75)。
4. preparation method according to claim 1, which is characterized in that a concentration of 5mM of the phosphate buffer, pH are
7.4。
5. preparation method according to claim 1, which is characterized in that the aperture of the miillpore filter is 0.22 μm.
6. according to claim 1-5 any one of them preparation methods, which is characterized in that the cholesterol-PEG2000-RGD's
Addition and the molar ratio of phosphatide are 1：20.
7. according to claim 1-6 any one of them preparation methods, which is characterized in that the matter of phosphatide and F-68 in step (1)
Amount is than being 8：1.
8. according to claim 1-7 any one of them preparation methods, which is characterized in that the phosphatide and perfluoro bromide octane
(PFOB) mass ratio is 1:2.5-1:5.
9. the RGD- perfluorocarbon breast MRI developers being prepared according to any one of claim 1-7 the methods.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810351309.3A CN108434464A (en) | 2018-04-17 | 2018-04-17 | A kind of RGD- perfluorocarbons breast magnetic resonance imaging developer and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810351309.3A CN108434464A (en) | 2018-04-17 | 2018-04-17 | A kind of RGD- perfluorocarbons breast magnetic resonance imaging developer and its preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108434464A true CN108434464A (en) | 2018-08-24 |
Family
ID=63200940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810351309.3A Pending CN108434464A (en) | 2018-04-17 | 2018-04-17 | A kind of RGD- perfluorocarbons breast magnetic resonance imaging developer and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108434464A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109157663A (en) * | 2018-10-11 | 2019-01-08 | 中国科学院武汉物理与数学研究所 | A kind of RGD- perfluocarbon-nano silicon spheres129Xe magnetic resonance imaging developer and its preparation method and application |
| CN110559456A (en) * | 2019-10-28 | 2019-12-13 | 中国科学院武汉物理与数学研究所 | Preparation method of 19F-Boehringer nanoemulsion magnetic resonance imaging developer |
| CN117483931A (en) * | 2024-01-03 | 2024-02-02 | 四川钛程钛业有限公司 | Explosion welding preparation method of novel marine metal composite board |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070258908A1 (en) * | 2006-04-27 | 2007-11-08 | Lanza Gregory M | Detection and imaging of target tissue |
| CN105770915A (en) * | 2016-03-02 | 2016-07-20 | 哈尔滨医科大学 | Nanometer 1H-19F-31P multi-nuclear magnetic resonance molecular imaging probe transmitted through respiratory tract and preparing method thereof |
-
2018
- 2018-04-17 CN CN201810351309.3A patent/CN108434464A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070258908A1 (en) * | 2006-04-27 | 2007-11-08 | Lanza Gregory M | Detection and imaging of target tissue |
| CN105770915A (en) * | 2016-03-02 | 2016-07-20 | 哈尔滨医科大学 | Nanometer 1H-19F-31P multi-nuclear magnetic resonance molecular imaging probe transmitted through respiratory tract and preparing method thereof |
Non-Patent Citations (5)
| Title |
|---|
| CELINE GIRAUDEAU等: "19F molecular MR imaging for detection of brain tumor angiogenesis: in vivo validation using targeted PFOB nanoparticles", 《ANGIOGENESIS》 * |
| HUA PAN等: "Programmable nanoparticle functionalization for in vivo targeting", 《THE FASEB JOURNAL·RESEARCH COMMUNICATION》 * |
| JAN WOLBER等: "Perfluorocarbon Emulsions as Intravenous Delivery Media for Hyperpolarized Xenon", 《MAGNETIC RESONANCE IN MEDICINE》 * |
| M. YILDIRIM等: "in vivo Molecular Imaging of Angiogenesis in Murine Urogenital Organs with Targeted Perfluorocarbon Nanoparticles and 19F ultrafast Turbo Spectroscopic Imaging (F-uTSI)", 《RESEARCH GATE》 * |
| SEBASTIAN TEMME等: "Non-Invasive Imaging of Early Venous Thrombosis by 19F MRI Using Targeted Perfluorocarbon Nanoemulsions", 《CIRCULATION》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109157663A (en) * | 2018-10-11 | 2019-01-08 | 中国科学院武汉物理与数学研究所 | A kind of RGD- perfluocarbon-nano silicon spheres129Xe magnetic resonance imaging developer and its preparation method and application |
| CN110559456A (en) * | 2019-10-28 | 2019-12-13 | 中国科学院武汉物理与数学研究所 | Preparation method of 19F-Boehringer nanoemulsion magnetic resonance imaging developer |
| CN117483931A (en) * | 2024-01-03 | 2024-02-02 | 四川钛程钛业有限公司 | Explosion welding preparation method of novel marine metal composite board |
| CN117483931B (en) * | 2024-01-03 | 2024-04-23 | 四川钛程钛业有限公司 | Explosion welding preparation method of novel marine metal composite board |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hu et al. | Dysprosium-modified tobacco mosaic virus nanoparticles for ultra-high-field magnetic resonance and near-infrared fluorescence imaging of prostate cancer | |
| Huang et al. | Multimodality and nanoparticles in medical imaging | |
| Pourtau et al. | Antibody-functionalized magnetic polymersomes: in vivo targeting and imaging of bone metastases using high resolution MRI | |
| Chen et al. | Plectin-1 targeted dual-modality nanoparticles for pancreatic cancer imaging | |
| CN108434464A (en) | A kind of RGD- perfluorocarbons breast magnetic resonance imaging developer and its preparation method and application | |
| CN105112052B (en) | A kind of preparation method of fluorescence magnetic resonance bimodal carbon quantum dot | |
| Kim et al. | Gadolinium-chelate nanoparticle entrapped human mesenchymal stem cell via photochemical internalization for cancer diagnosis | |
| CN106267241A (en) | A kind of multi-functional multi-modal tumour-specific targeting inversion of phases Nano microsphere photoacoustic contrast agent and application thereof | |
| Swider et al. | Clinically-applicable perfluorocarbon-loaded nanoparticles for in vivo photoacoustic, 19F magnetic resonance and fluorescent imaging | |
| Bober et al. | Application of dendrimers in anticancer diagnostics and therapy | |
| Xu et al. | Monodisperse magnetite nanoparticles coupled with nuclear localization signal peptide for cell‐nucleus targeting | |
| Luengo Morato et al. | Recent advances in multimodal molecular imaging of cancer mediated by hybrid magnetic nanoparticles | |
| CN106692993A (en) | Specific targeted magnetic resonance-optical dual-mode imaging probe and preparation method thereof | |
| Maghsoudinia et al. | Folic acid-functionalized gadolinium-loaded phase transition nanodroplets for dual-modal ultrasound/magnetic resonance imaging of hepatocellular carcinoma | |
| Zhong et al. | Contrast-enhanced photoacoustic imaging using indocyanine green-containing nanoparticles | |
| CN105079826A (en) | Preparation method and application of RGD@BBN double-targeted MR (magnetic resonance)/optical dual-mode molecular probe | |
| US20180161461A1 (en) | Rare Earth Oxide Particles and Use Thereof in Particular In Imaging | |
| Li et al. | The renal clearable magnetic resonance imaging contrast agents: state of the art and recent advances | |
| Ma et al. | Three-dimensional angiography fused with CT/MRI for multimodal imaging of nanoparticles based on Ba 4 Yb 3 F 17: Lu 3+, Gd 3+ | |
| Pudakalakatti et al. | Hyperpolarized MRI with silicon micro and nanoparticles: Principles and applications | |
| Jiang et al. | Novel gadopentetic acid-doped silica nanoparticles conjugated with YPSMA-1 targeting prostate cancer for MR imaging: an in vitro study | |
| CN104524602A (en) | Folate receptor targeting ultrasound contrast nanobubble and preparation method thereof | |
| Li et al. | Potential detection of cancer with fluorinated silicon nanoparticles in 19 F MR and fluorescence imaging | |
| CN104815341A (en) | Targeted polymer micelle magnetic nanoparticle, and preparation method and application thereof | |
| Nikolaev et al. | Magnetic epidermal growth factor conjugate for targeted delivery to grafted tumor in mouse model |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180824 |